Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
PRLD
#2987
Prelude Therapeutics Incorporated
2.7
6
-5.80%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
-5.80%
Variazione Mensile
+28.37%
Variazione di 6 mesi
+113.95%
Variazione Annuale
+253.85%
Chiusura Precedente
2.9
3
Open
2.7
6
Bid
Ask
Low
2.7
6
High
2.7
6
Volume
3
Mercati
Mercato Azionario Statunitense
Salute
PRLD
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
32.6 M
36.2 M
36.5 M
42.06 M
42.3 M
173.4 M
Valuation ratios
Enterprise value
3.11 B
561.19 M
209.92 M
198.24 M
57.85 M
124 M
Price to earnings ratio
—
—
-2.06
-2.01
-0.76
-2.7
Price to sales ratio
—
—
—
—
13.81
—
Price to cash flow ratio
—
—
-2.84
-2.29
-0.94
-3.15
Price to book ratio
—
—
1.22
1.04
0.74
1.26
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.25
0.37
0.52
0.44
0.72
0.87
Return on equity %
0.27
0.39
0.59
0.51
0.97
1.28
Return on invested capital %
10.89 K
8 576.16
4 233.67
2 161.61
1 600.72
—
Gross margin %
100
—
—
—
100
—
Operating margin %
534.21 K
—
—
—
1 995.91
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
517.54 K
—
—
—
1 816.76
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
19.41
15.37
9.42
10.79
5.3
17.36
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
—
—
—
0.03
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
1.77
1.77
1.36
1.32
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
7.87
7.3
1.76
4.75
Net current asset value per share
—
—
4.31
3.9
1.79
4.92
Tangible book value per share
—
—
4.13
3.93
1.73
4.86
Working capital per share
—
—
3.86
3.54
1.45
3.81
Book value per share
—
—
4.13
3.93
1.73
4.86
Notizie
Azioni Prelude Therapeutics ricevono conferma del rating Market Outperform da Citizens
Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens
Il titolo di Prelude Therapeutics balza dopo l’approvazione FDA per farmaco anticancro
Prelude Therapeutics stock surges after FDA clears IND for cancer drug
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Mizuho aggiorna il rating delle azioni Incyte a Outperform grazie ai promettenti dati ASH
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus
Rating delle azioni Prelude Therapeutics confermato a Market Outperform da Citizens
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens
Il titolo Incyte raggiunge il massimo annuale a 108,81 USD
Trascrizione della relazione sugli utili: Prelude Therapeutics Q3 2025 mostra stabilità del titolo